DCAT Sustainability Leaders (eBook)
The first edition of The Sustainability Leaders, an eBook presented by DCAT, is now available. AustinPx is one of the sustainability leaders highlighted in this eBook, as well as the efforts of other DCAT Member Companies that are contributing positively to the environment. You shouldn’t miss this opportunity to discover the praiseworthy initiatives being taken…
Read MoreHow Sustainable Practices in Pharma Drive Long-term Growth
Embracing sustainability is not just socially responsible but also strategically beneficial, driving long-term financial returns and strengthening relationships with patients and the broader community. At AustinPx, sustainability, innovation, and client-centricity are our pillars as a CDMO. Our KinetiSol Technology doesn’t just offer a more sustainable method for developing poorly soluble drug candidates, it provides improved performance, accelerated…
Read MoreHow Prioritizing Sustainability Efforts Yields Long-term Growth in Drug Manufacturing
Pharmaceutical companies that invest strategically in sustainability initiatives will differentiate themselves in a competitive market. Implementing these practices ensures a robust and long-term market position, enabling stakeholders across the value chain to overcome post-COVID challenges, innovate, and secure a more sustainable future for the industry. With KinetiSol Technology, drug developers have a better option for developing…
Read MoreHow Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks article)
AustinPx’s Justin Keen, Senior Vice President, Operations explores the scaling up of KinetiSol Technology. This innovative, solvent-free process rapidly transforms active pharmaceutical ingredients into high-quality amorphous solid dispersions, enhancing solubility and bioavailability. KinetiSol simplifies scale-up by controlling a single variable – shear rate – making the transition from lab-scale to commercial production seamless and efficient. Keen…
Read MoreTrends in amorphous solid dispersion drug products approved by the U.S. FDA between 2012 and 2023
In a recent publication, the trends in ASD drug products over a 12-year period from 2012 to 2023 were analyzed. The review highlights the role of AustinPx’s KinetiSol Technology, a solvent-free process that provides significant advantages over traditional methods like spray drying. KinetiSol’s ability to process thermolabile compounds and improve drug stability and bioavailability is emphasized…
Read MorePharma Matters Q&A: AustinPx, Talking Next-Gen Amorphous Dispersion Technology
Dave Miller, Chief Scientific Officer of AustinPx, discusses in a recent Q&A why our innovative KinetiSol Technology will revolutionize amorphous solid dispersions (ASDs) for poorly soluble APIs. Unlike traditional spray drying, KinetiSol uses a solvent-free process, enhancing stability and bioavailability by preventing phase separation and directly dissolving drugs in polymers. Miller explains how KinetiSol supports sustainable manufacturing…
Read MoreDave Miller: Pioneer in Pharmaceutical Innovation
Dave Miller, the Chief Scientific Officer (CSO) at AustinPx, is a leading figure in pharmaceutical science. His career path reflects his dedication, innovation, and commitment to excellence. From his early days as a chemical engineering student at the University of Texas to his key role at AustinPx, Miller’s journey is a story of scientific curiosity,…
Read MoreLess Mess, Less Stress, Best Expressed: A Superior Alternative To Spray Drying
In a recent article, Chris Brough, CTO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Unlike spray drying, which relies on organic solvents and nitrogen, KinetiSol uses a solvent-free process that directly dissolves drugs in polymers, preventing phase separation and enhancing stability and bioavailability. KinetiSol streamlines the scale-up…
Read MoreWinning Strategies For Oral Dosage Form Development And Manufacturing
In a recent article, Dave Miller, CSO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Failure to identify a compound’s red flags—bioavailability, stability, processability, etc.—early in development often manifests as program delays or failures. These setbacks can be avoided through complete molecular characterization, which can de-risk development and…
Read MorePushing the Boundaries of Drug Development: Is Lipinski’s Rule of Five Still Relevant?
Dave Miller, Ph.D., CSO of AustinPx, challenges the continued relevance of Lipinski’s Rule of Five (Ro5) in today’s pharmaceutical landscape. As technologies like AI and in-silico modeling reshape drug discovery, modern compounds often deviate from Ro5 guidelines yet demonstrate significant therapeutic potential. However, these nonconforming molecules can face hurdles in development due to solubility and…
Read MorePharma Trends and Predictions for 2025: An incoming CEO’s perspective
Elizabeth Hickman, CEO of AustinPx, outlines six key trends shaping the CDMO landscape in 2025. From the rise of GLP-1s and AI-driven molecules to growing interest in patient-centric dosage forms and IP-enhancing services, the article highlights how CDMOs must evolve to stay competitive. Hickman emphasizes the need for advanced formulation technologies, scalable processes, and a…
Read MoreKinetiSol Technology: A Sustainable and Efficient Revolution in Bioavailability Enhancement
CDMOs and Small Molecule Challenges: Navigating the Impact of the Inflation Reduction Act
Breaking all the Rules – Pushing the Boundaries of Lipinski’s Rule of 5
Lipinski’s Rule of 5 is a guideline in drug discovery that helps predict if a molecule is likely to be orally bioavailable. It’s a set of criteria based on molecular weight, hydrogen bond donors and acceptors, and lipophilicity that, when violated, suggest a compound might have poor absorption or permeation. However, new molecules emerging from…
Read MoreA Shifting CDMO Landscape: The Rise of High-Science, High-Touch
In a rapidly evolving drug development environment, capacity alone is no longer enough. In this article, AustinPx Chief Executive Officer Elizabeth Hickman unpacks how the CDMO landscape is shifting toward a “high-science, high-touch” model, one that prioritizes deep technical expertise alongside strong client collaboration. The article argues that success now hinges on more than just…
Read MoreChoosing the Best Amorphous Dispersion Path Before It Costs You
AustinPx examines why early amorphous solid dispersion (ASD) technology selection can have a major impact on cost, timelines, and long-term product value. As more oral small molecules face poor solubility, low exposure, food effect risk, and dose form challenges, a single technology screen may not provide enough information to choose the strongest development path. The…
Read MoreBuilding Resilience: CDMO Strategies for Drug Supply Chain Stability
In this article, AustinPx CEO Elizabeth Hickman highlights the critical role small-molecule CDMOs play in stabilizing today’s strained pharmaceutical supply chains. With more than 250 essential drugs in shortage, CDMOs must balance agility with scientific rigor to meet rising demand, regulatory pressures, and funding challenges. Hickman explores how high-science, high-touch strategies, scalable manufacturing, and patient-centric…
Read MorePartnerships To Be Precise
Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) examine how the rise of precision medicine is reshaping the role of CDMOs. As drug developers take on increasingly complex, patient-targeted therapies, formulation strategies must evolve to meet the moment. From multi-component ASDs to lipid-based delivery systems, CDMOs must now deliver tailored solutions that match each…
Read MoreSustainability in Pharma Manufacturing: Strategic Benefits of Going Green
In this piece, AustinPx’s CEO, Elizabeth Hickman, explores how sustainability is becoming a strategic priority across the pharmaceutical supply chain. From renewable energy and waste reduction to IoT and blockchain-based transparency, companies are finding that going green is not just good for the planet, it improves supply chain resilience and profitability. Hickman highlights how CDMOs…
Read MorePrecision Without a Playbook: How Agile CDMOs Enable Personalised Drug Development
In this article, Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) discuss how as precision medicine becomes the new standard, traditional development models are falling short. This article highlights the challenges of formulating and manufacturing personalised therapies, from poor solubility and stability issues to the growing need for patient-friendly dosage forms. Agile CDMOs are…
Read More